Last reviewed · How we verify
Phase B: Triplixam / Elestar HCT
Triplixam/Elestar HCT is a fixed-dose combination that lowers blood pressure through multiple mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuretic action.
Triplixam/Elestar HCT is a fixed-dose combination that lowers blood pressure through multiple mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuretic action. Used for Hypertension (marketed formulation for blood pressure control).
At a glance
| Generic name | Phase B: Triplixam / Elestar HCT |
|---|---|
| Also known as | Triple Single Pill Combination: Triplixam / Elestar HCT |
| Sponsor | National Institute of Cardiology, Warsaw, Poland |
| Drug class | Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic) |
| Target | L-type calcium channels, angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The combination product contains three antihypertensive agents working synergistically: a calcium channel blocker (diltiazem or similar) that reduces vascular smooth muscle contraction, an ARB (likely valsartan or similar) that blocks angiotensin II-mediated vasoconstriction and sodium retention, and hydrochlorothiazide (HCT), a thiazide diuretic that reduces blood volume and sodium levels. This triple mechanism provides additive blood pressure reduction for patients requiring intensive antihypertensive therapy.
Approved indications
- Hypertension (marketed formulation for blood pressure control)
Common side effects
- Peripheral edema
- Dizziness
- Headache
- Hypokalemia
- Hyperuricemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: